Valeant Grew by Buying Drugs and Raising Their Prices
A pharmaceutical company pursued acquisitions while cutting research spending, then raised prices on the drugs it acquired. The model worked until the pricing became politically untenable.
The Strategy
Valeant Pharmaceuticals argued explicitly that internal drug research destroyed value. Research is expensive, slow, and mostly fails, so the return on research spending across the industry is poor.
The alternative was to acquire companies with already approved drugs, eliminate their research operations and overhead, and raise prices on the acquired products.
Stated in isolation, the capital allocation logic is not absurd. If research generates returns below the cost of capital, redirecting that spending is defensible. The question is what happens to an industry where everyone reasons that way.
Why It Produced Such Strong Numbers
The reported results were exceptional, and the mechanics explain most of it. Each acquisition added revenue immediately. Cost cuts at acquired companies improved margins quickly. Price increases on acquired drugs added revenue with essentially no incremental cost.
The company emphasised adjusted earnings that excluded acquisition related charges and amortisation of acquired intangibles, producing a figure substantially above reported earnings.
Amortisation of acquired drug rights is the cost of the asset generating the revenue. Excluding it presents the revenue without the cost of obtaining it.
The Constraint
The model faced an arithmetic limit. Growth from acquisitions requires each deal to be large enough to move a growing base, so acquisitions must accelerate in size.
Price increases on acquired drugs are also finite, constrained eventually by payers, competitors, and politics. Several substantial price increases on acquired treatments attracted congressional attention and public criticism, which made continued increases untenable.
The Specialty Pharmacy Issue
Additional scrutiny concerned the company's relationship with a specialty pharmacy that distributed its products. Questions arose about the nature of the relationship, how it was disclosed, and how it affected reported revenue.
The company had presented the arrangement as an arm's length distribution relationship, and the closeness of the connection raised questions about whether revenue recognised through that channel reflected genuine third party demand.
The Collapse
The shares fell by the large majority of their value over roughly a year. Debt taken on to fund acquisitions became the binding constraint once growth stopped, since the leverage had been sized against continued expansion. Management changed and the company was restructured and renamed.
What to Take From It
Three analytical checks apply. Where a company emphasises adjusted earnings, identify what is excluded and whether those items are genuinely non recurring or are the ordinary cost of the strategy.
Where growth comes from acquisitions, find organic growth separately. And where leverage is sized against projected growth, ask what happens to the debt if growth stops, because the debt does not adjust.
The Bottom Line
Valeant bought revenue, cut the research behind it, raised prices, and excluded the cost of the acquired assets from headline earnings. The strategy required perpetual acquisition, and the leverage assumed it would continue.